Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621 1642 1643 1646 1671
This examiner grants 69% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18461191 | MATERIALS AND METHODS FOR IMPROVED SINGLE CHAIN VARIABLE FRAGMENTS | Non-Final OA | Janssen Biotech, Inc. |
| 18029798 | GENE CORRECTION FOR X-CGD IN HEMATOPOIETIC STEM AND PROGENITOR CELLS | Non-Final OA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY |
| 18237210 | SITE-SPECIFIC QUANTITATION OF DRUG CONJUGATIONS | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 17611758 | Metabolite Delivery for Modulating Metabolic Pathways of Cells | Final Rejection | Arizona Board of Regents on Behalf of Arizona State University |
| 18319279 | SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES | Non-Final OA | Genzyme Corporation |
| 17093486 | RIBONUCLEOPROTEIN TRANSFECTION AGENTS | Final Rejection | LIFE TECHNOLOGIES CORPORATION |
| 17627613 | METHOD OF TREATING NEOPLASTIC DISEASES WITH A CDC42-SPECIFIC INHIBITOR | Non-Final OA | Children's Hospital Medical Center |
| 17927225 | LIQUID FORMULATION OF LONG-ACTING CONJUGATE OF GLP-2 | Final Rejection | HANMI PHARM. CO., LTD. |
| 17759139 | VACCINATION AGAINST ANTIGENS INDUCED IN PATHOGEN-INFECTED CELLS | Non-Final OA | University of Miami |
| 18258343 | Therapeutic RNA for Treating Cancer | Final Rejection | BioNTech SE |
| 18427293 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES AND USES THEREOF | Non-Final OA | MEDIMMUNE LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy